Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Varela

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
European Journal of Medicinal Chemistry|July 2, 2013
Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agentsEnrique Torres, Elsa Moreno-Viguri, Silvia Galiano, et al.
European Journal of Medicinal Chemistry|January 29, 2013
New oxidovanadium(IV) N-acylhydrazone complexes: promising antileishmanial and antitrypanosomal agentsJulio Benítez, Aline Cavalcanti de Queiroz, Isabel Correia, et al.
Molecules (Basel, Switzerland)|August 15, 2015
3-H-[1,2]Dithiole as a New Anti-Trypanosoma cruzi Chemotype: Biological and Mechanism of Action StudiesMarcos Couto, Carina Sánchez, Belén Dávila, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Identification of a new amide-containing thiazole as a drug candidate for treatment of Chagas' diseaseGuzmán Álvarez, Javier Varela, Eugenia Cruces, et al.
European Journal of Medicinal Chemistry|May 13, 2017
Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological propertiesAngela Guerra, Pedro Gonzalez-Naranjo, Nuria E Campillo, et al.
European Journal of Medicinal Chemistry|October 5, 2010
Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activityGuzmán Alvarez, Beatriz Aguirre-López, Javier Varela, et al.
Pharmaceutics|December 31, 2025
Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell TherapyJavier Varela-González-Aller, Mario Andrés Sánchez-Salinas, Iñaki Troconiz, et al.
Journal of Medicinal Chemistry|April 23, 2014
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activityGuzmán Álvarez, Javier Varela, Pablo Márquez, et al.
Chemmedchem|October 24, 2015
Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget ActivityElena Aguilera, Javier Varela, Estefanía Birriel, et al.
BMC Pharmacology & Toxicology|December 20, 2019
Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegansFabiana Gomes Nascimento Soares, Gabriela Göethel, Luciano Porto Kagami, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
European Journal of Medicinal Chemistry|July 2, 2013
Novel quinoxaline 1,4-di-N-oxide derivatives as new potential antichagasic agentsEnrique Torres, Elsa Moreno-Viguri, Silvia Galiano, et al.
European Journal of Medicinal Chemistry|January 29, 2013
New oxidovanadium(IV) N-acylhydrazone complexes: promising antileishmanial and antitrypanosomal agentsJulio Benítez, Aline Cavalcanti de Queiroz, Isabel Correia, et al.
Molecules (Basel, Switzerland)|August 15, 2015
3-H-[1,2]Dithiole as a New Anti-Trypanosoma cruzi Chemotype: Biological and Mechanism of Action StudiesMarcos Couto, Carina Sánchez, Belén Dávila, et al.
Antimicrobial Agents and Chemotherapy|December 17, 2014
Identification of a new amide-containing thiazole as a drug candidate for treatment of Chagas' diseaseGuzmán Álvarez, Javier Varela, Eugenia Cruces, et al.
European Journal of Medicinal Chemistry|May 13, 2017
Novel Imidazo[4,5-c][1,2,6]thiadiazine 2,2-dioxides as antiproliferative trypanosoma cruzi drugs: Computational screening from neural network, synthesis and in vivo biological propertiesAngela Guerra, Pedro Gonzalez-Naranjo, Nuria E Campillo, et al.
European Journal of Medicinal Chemistry|October 5, 2010
Massive screening yields novel and selective Trypanosoma cruzi triosephosphate isomerase dimer-interface-irreversible inhibitors with anti-trypanosomal activityGuzmán Alvarez, Beatriz Aguirre-López, Javier Varela, et al.
Pharmaceutics|December 31, 2025
Towards Personalized Lymphodepletion: A Population Pharmacokinetic Fludarabine Model in Patients Receiving CAR T-Cell TherapyJavier Varela-González-Aller, Mario Andrés Sánchez-Salinas, Iñaki Troconiz, et al.
Journal of Medicinal Chemistry|April 23, 2014
Optimization of antitrypanosomatid agents: identification of nonmutagenic drug candidates with in vivo activityGuzmán Álvarez, Javier Varela, Pablo Márquez, et al.
Chemmedchem|October 24, 2015
Potent and Selective Inhibitors of Trypanosoma cruzi Triosephosphate Isomerase with Concomitant Inhibition of Cruzipain: Inhibition of Parasite Growth through Multitarget ActivityElena Aguilera, Javier Varela, Estefanía Birriel, et al.
BMC Pharmacology & Toxicology|December 20, 2019
Novel coumarins active against Trypanosoma cruzi and toxicity assessment using the animal model Caenorhabditis elegansFabiana Gomes Nascimento Soares, Gabriela Göethel, Luciano Porto Kagami, et al.
Pageof 5